SNX10 and ovarian carcinoma: Searching the GEPIA2 and Kaplan–Meier Plotter databases revealed that SNX10 is substantially expressed in ovarian cancer and has a negative correlation with progression-free survival (PFS) or overall survival (OS) of ovarian cancer (Figure 1E).